SCHEMBL1492360

SCHEMBL1492360

CCOC(=O)c1c(N)ccn1-c1ccc(B2OC(C)(C)C(C)(C)O2)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
UCHL1 P09936 1/20 0.42
KDM4E B2RXH2 2/20 0.38
LPL P06858 2/20 0.37
LIPG Q9Y5X9 2/20 0.37
MAPK1 P28482 1/20 0.37
CA1 P00915 4/20 0.37
CA2 P00918 4/20 0.37
CA9 Q16790 4/20 0.37
F11 P03951 2/20 0.36
LMNA P02545 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
MAOA P21397 1/20 0.36
HPGD P15428 2/20 0.36
HTT P42858 1/20 0.36
P4HB P07237 1/20 0.36
PDE4D Q08499 1/20 0.36
ALDH1A1 P00352 4/20 0.35
GAA P10253 1/20 0.35
MAPT P10636 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1492230 0.80 LMNA (0.57) KDM4EMAPK1CA1CA2CA9
SCHEMBL12496041 0.80 UCHL1 (0.43) UCHL1LPLLIPGMAPK1CA1
SCHEMBL1492324 0.78 HIF1A (0.38) UCHL1KDM4ELPLLIPGCA1
SCHEMBL1492363 0.78 CASP3 (0.47) KDM4ECA9LMNACYP1A2CYP3A4
SCHEMBL18955943 0.78 GABRA2 (0.51) KDM4EMAPK1CA1CA2CA9
SCHEMBL19643804 0.78 ALDH1A1 (0.57) KDM4ELMNACYP1A2CYP3A4MAOA
SCHEMBL3686298 0.77 CA1 (0.53) UCHL1LPLLIPGCA1CA2
Hydrochloric Acid SCHEMBL1492383 0.77 CASP3 (0.46) KDM4ECA9LMNACYP1A2CYP3A4
SCHEMBL1492332 0.77 SMN1; SMN2 (0.52) KDM4EMAPK1CA9LMNACYP1A2
Hydrochloric Acid SCHEMBL1492314 0.76 SMN1; SMN2 (0.51) KDM4EMAPK1CA9LMNACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2475660-A1 PYRROLO-PYRIDINE DERIVATIVES AS ACTIVATORS OF AMPK GlaxoSmithKline LLC (US) 2012-07-18 EP disclosed
US-20120172333-A1 PYRROLO-PYRIDINE DERIVATIVES AS ACTIVATORS OF AMPK GLAXOSMITHKLINE LLC (US) 2012-07-05 US disclosed
US-20120172333-A1 PYRROLO-PYRIDINE DERIVATIVES AS ACTIVATORS OF AMPK GLAXOSMITHKLINE LLC (US) 2012-07-05 US disclosed
US-20120172333-A1 PYRROLO-PYRIDINE DERIVATIVES AS ACTIVATORS OF AMPK GLAXOSMITHKLINE LLC (US) 2012-07-05 US disclosed
WO-2011029855-A1 PYRROLO-PYRIDINE DERIVATIVES AS ACTIVATORS OF AMPK GLAXOSMITHKLINE LLC (US) 2011-03-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120172333-A1 PYRROLO-PYRIDINE DERIVATIVES AS ACTIVATORS OF AMPK PRKAB1, PRKAG1, PRKAB2 UCHL1 4474/4885KDM4E 1540/4885LPL 1611/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.